Donate
T1International Statement on Brexit

T1International Statement on Brexit

Facebook Google LinkedIn Twitter

As a UK-based, patient-led advocacy charity that exists to champion the rights of people with type 1 diabetes everywhere in the world, T1International is only too aware of how high drug prices and a lack of support services can negatively impact upon people living with chronic health conditions such as type 1 diabetes.

One such country where we advocate strongly defending the rights of patients is the USA. The free market healthcare model of the USA, which assumes that consumers have choice and that the market will set the price, is failing patients. Patients frequently do not have a choice about the medicine they need, and, as demonstrated all too clearly by out-of-control insulin prices - which have tripled over the past ten years - the 'free market' only works when competition is a factor and consumers can choose not to buy the product.

Pharmaceutical companies spend billions of dollars on lobbying for their interests and hold sway at the highest levels of government. Citizens rely on medical insurance tied to their employment, frequently afraid to change jobs for fear of losing some aspect of critical medical coverage. A study carried out in 2019 found that 66.5% of all personal bankruptcies in the USA were tied to medical issues. Patients are forced to pay high out-of-pocket costs for their medicine and we see people dying from rationing insulin, or suffering devastating and entirely preventable complications because they cannot reliably or affordably access their essential medicine or supplies. In a T1International study carried out in 2018, we found that 25% of American respondents had been forced to ration their insulin due to cost.

As the UK moves to the next phase of Brexit, we deeply hope that British citizens will reap the benefits to the NHS promised by those who campaigned to leave the EU. However, we also recognise that the UK is now in a vulnerable position as it moves forward to the negotiation of trade deals. Other countries will understandably seek to secure favourable terms for their own interests and regardless of current assurances, we have grave concerns at what might be 'on the table' as the negotiations take place.

The NHS has long been regarded as a jewel in the crown of the UK and the envy of many other countries. Healthcare free at the point of use and where the poorest as well as the richest are looked after should be something to celebrate and fiercely defend.

We stand ready to hold the UK government to account on the provision of healthcare for UK citizens with type 1 diabetes over the coming months and years. We will strongly resist any erosion of the current provision of essential medicine and supplies, medical devices or support services for patients with type 1 diabetes in the UK.

Related posts:

T1International Statement on COVID-19

T1International Statement on COVID-19

As the world grapples with the effects of a global pandemic, the situation is evolving quickly and the short and long-term impacts are still unclear. What is clear is that the COVID-19 crisis stresses the need to approach healthcare as a human right. The crisis also emphasizes the need for international cooperation to fix global health problems. There must be global solidarity in the fight for #insulin4all and universal access to healthcare. Read more

T1International Statement on Lilly & Novo's ''Generic Insulin''

T1International Statement on Lilly & Novo's ''Generic Insulin''

Patient-led activism is working. Today Eli Lilly announced that in response to criticism of high prices, the company will sell a version of Humalog insulin for half price. We are pleased to see this result after continual and dedicated efforts by non-pharma funded patient advocates to ensure list price of insulin goes down. While half-price is an improvement, it's still an unaffordable price for so many, considering most people need at least 2 vials each month.
Read more

T1International Statement on Novo Nordisk and Sanofi Price Hikes

T1International Statement on Novo Nordisk and Sanofi Price Hikes

Sanofi and Novo Nordisk are celebrating the New Year with fresh price hikes on their decades-old insulin products. “Sanofi increased the price of its three main insulin brands by between 4.4 %- 5.2 % last week, while Novo Nordisk increased the price of its insulin products by just under 5% on Tuesday,” the Financial Times article said. Once again, shareholder profits will be increased on the backs of people with diabetes. Read more

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

Nicole Smith-Holt Statement on Eli Lilly Helpline Announcement

I vow to continue to fight for the rights and lives of all people with diabetes. I am doing all this in honor of my son, Alec Raeshawn Smith. I invite Lilly to work with me and non-industry funded organizations like T1International so that we can find real solutions to ensure #insulin4all. Mr. Mason, I am still waiting to hear from you. Read more

T1International Statement on Walmart Insulin

T1International Statement on Walmart Insulin

Recently, the American Diabetes Association issued a white paper on Insulin Access and Affordability by their Working Group. While we continue to applaud the American Diabetes Association for speaking out about the high cost of insulin, we remain concerned with their approach and some of the recommendations in their paper.
Read more